Weekly epoetin alfa during adjuvant chemotherapy for breast cancer: Effect on hemoglobin levels and quality of life

Clinical Breast Cancer

Volumn 6, Issue 2, 2005, Pages 132-142

  Hudis, Clifford A ^a   Vogel, Charles L ^b   Gralow, Julie R ^c   Williams, Denise ^d   Abrams, Martin ^e   Abramson, Jonathan ^e   Adams, John ^e   Adler, Kent ^e   Afifi, Mahmoud ^e   Ahmed, Fakhiuddin ^e   Ahuja, Harish G ^e   Albro, Judith A ^e   Alden, Mitchell ^e   Alexander, Michael ^e   Ali, Mohammed Y ^e   Al Jazayrly, Ghassan ^e   Ambinder, Anderson M ^e   Amin, V C ^e   Anagnost, John ^e   Ashigbi, Michael Y ^e   Atiq, Omar T ^e   Auchus, Mary Lou ^e   Badolato, Craig J ^e   Baeker, Thomas ^e   Balaban, Edward ^e   Bank, Bruce ^e   Barai, Bharat H ^e   Barreras, Luis R ^e   Bassett Jr , Wilbur B ^e   Beall, Charles L ^e   Beck, J Thaddeus ^e   Belenkov, Elliot M ^e   Bell, Donna A ^e   Ben Zeev, Dan ^e   Berkovic, Michael ^e   Berman, Dennis ^e   Bhanja, Utpal K ^e   Bigman, Karin ^e   Biss, Roger T ^e   Biswas, Nanda ^e   Blankstein, Kenneth ^e   Blayney, Douglas ^e   Borges, Virginia F ^e   Bosserman, Linda D ^e   Bott, Cordell J ^e   Bottino, Gino C ^e   Boyle, L Eamonn ^e   Brahmamdam, Ranga ^e   Brate, Elizabeth J ^e   Brinkley, William ^e   Briscoe, Katheleen ^e   Broadway, Paula ^e   Browne, Marcia J ^e   Burns, Patricia ^e   Burton, Gary V ^e   Butala, Atul ^e   Byrne, Patricia ^e   Caggiano, Vincent ^e   Camacho, Elber ^e   Campbell, Laura C ^e   Campos, Luis ^e   Caputto, Salvadore ^e   Carlson, Mark ^e   Carmosino, Linda ^e   Carrellas, Jean M ^e   Caskey, Jennifer H ^e   Cathcart Rake, William ^e   Chahin, Majd ^e   Chamberlain, Kerry E ^e   Charu, Veena ^e   Chawla, Sant P ^e   Chen, Alice P ^e   Chernicoff, David ^e   Chhabra, Gurdeep ^e   Chinnasami, Bernard ^e   Choate, Jennifer ^e   Choksi, Janak ^e   Ciarolla, Anthony ^e   Cobb, Patrick ^e   Cobos, Everardo ^e   Coluzzi, Paul ^e   Conroy Jr , John D ^e   Corral, Javier ^e   Costanzi, John J ^e   Coughenour, Mark ^e   Creekbaum, Greenville ^e   Crews, Jennie R ^e   Crowell, Edward B ^e   Cunningham, William ^e   Damle, Snehal A ^e   Davidson, Sheldon ^e   Deen, Cathy ^e   DeLeo Jr , Michael ^e   DelPrete, Salvatore A ^e   DeMattia, Michael ^e   Deo, Eknath ^e   Dexeus, Francisco H ^e   Dobrzynski, Robert F ^e   Dosik, Gary ^e   more..

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b Cancer Research Network   (United States)

^c SEATTLE CANCER CARE ALLIANCE   (United States)

^d Ortho Biotech Products LP   (United States)

^e NONE

Author keywords

Anemia; Fatigue; Functional assessment of cancer therapy anemia scale; Linear analog scale assessment; Transfusion reductions

Indexed keywords

ANTINEOPLASTIC AGENT; IRON; RECOMBINANT ERYTHROPOIETIN;

ADULT; ALOPECIA; ANEMIA; ANOREXIA; ARTERY EMBOLISM; ARTHRALGIA; ARTICLE; BLOOD TRANSFUSION; BONE PAIN; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER STAGING; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; COMMUNITY CARE; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DAILY LIFE ACTIVITY; DIARRHEA; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; EDEMA; ENERGY; ERYTHROCYTE DISORDER; FATIGUE; FEMALE; FUNCTIONAL ASSESSMENT; GASTROINTESTINAL SYMPTOM; GRANULOCYTOPENIA; HEART ARREST; HEART INFARCTION; HEMOGLOBIN DETERMINATION; HOT FLUSH; HUMAN; HYPERTENSION; INJECTION SITE REACTION; INSOMNIA; LEG PAIN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MYALGIA; NAUSEA; PAIN; PHARYNGITIS; PHASE 4 CLINICAL TRIAL; QUALITY OF LIFE; RATING SCALE; STOMATITIS; THROMBOEMBOLISM; THROMBOPHLEBITIS; THROMBOSIS; UPPER RESPIRATORY TRACT INFECTION; VOMITING;

EID: 22144449587     PISSN: 15268209     EISSN: None     Source Type: Journal    
DOI: 10.3816/CBC.2005.n.015     Document Type: Article

References (41)

1. Groopman JE, Itri LM. Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst 1999; 91:1616-1634.
2. Birgegard G, Ludwig H, Nortier JWR, et al. Despite high prevalence of anemia and impact on performance status (PS), anemia treatment (Tx) rate is low in multiple myeloma/lymphoma (MM/L) patients (pts) according to European Cancer Anaemia Survey (ECAS). Blood 2002; 100(suppl):18b (Abstract #3521).
3. Ludwig H, Birgegard G, Barrett-Lee P, et al. Prevalence and management of anemia in patients (pts) with hematologic malignancies (HMs) and solid tumors (STs): results from the European Cancer Anaemia Survey (ECAS). Blood 2002; 100(suppl):234a-235a (Abstract #884).
4. Vogelzang NJ, Breitbart W, Cella D, et al. Patient, caregiver, and oncologist perceptions of cancer-related fatigue: results of a tripart assessment survey. Semin Hematol 1997; 34(suppl 2):4-12.
5. Curt GA, Breitbart W, Cella D, et al. Impact of cancer-related fatigue on the lives of patients: new findings from the Fatigue Coalition. Oncologist 2000; 5:353-360.
6. Caro JJ, Salas M, Ward A, et al. Anemia as an independent prognostic factor for survival in patients with cancer: a systematic, quantitative review. Cancer 2001; 91:2214-2221.
7. Cella D, Zagari MJ, Vandoros C, et al. Epoetin alfa treatment results in clinically significant improvements in quality of life in anemic cancer patients when referenced to the general population. J Clin Oncol 2003; 21:366-373.
8. Lawless GD, Ford JM. Cumulative prevalence of anemia in early-stage breast cancer (ESBC) patients. Blood 2000; 96(suppl):390b (Abstract #5447).
9. O'Shaughnessy JA, Vukelja SJ, Holmes FA, et al. Feasibility of quantifying the effects of epoetin alfa therapy on cognitive function in women with breast cancer undergoing adjuvant or neoadjuvant chemotherapy. Clin Breast Cancer 2005; 5:439-446.
10. Kirshner J, Hatch M, Hennessy D, et al. Anemia in stage II and III breast cancer patients treated with adjuvant doxorubicin and cyclophosphamide chemotherapy. Oncologist 2004; 9:25-32.
11. Jacobsen PB, Thors CL, Cawley M, et al. Relation of decline in hemoglobin to cognitive functioning and fatigue during chemotherapy treatment. Proc Am Soc Clin Oncol 2002; 21:386a (Abstract #1542).
12. Cella D, Mo F, Peterman A. Anemia, fatigue and quality of life in people with cancer and HIV infection. Blood 1996; 88(suppl 1):146a (Abstract #571).
13. Cella D. The Functional Assessment of Cancer Therapy-Anemia (FACT-An) scale: a new tool for the assessment of outcomes in cancer anemia and fatigue. Semin Hematol 1997; 34(suppl 2):13-19.
14. Cella D. Factors influencing quality of life in cancer patients: anemia and fatigue. Semin Oncol 1998; 25(suppl 7):43-46.
15. Yellen SB, Cella DF, Webster K, et al. Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system. J Pain Symptom Manage 1997; 13:63-74.
16. Demetri GD, Gabrilove JL, Blasi M, et al. Benefits of epoetin alfa in anemic breast cancer patients receiving chemotherapy. Clin Breast Cancer 2002; 3:45-51.
17. George MJ, Vahdat LT, Shasha D, et al. Increased hemoglobin and improved quality of life with once-weekly epoetin alfa in anemic breast cancer patients receiving concomitant or sequential chemoradiation. Proc Am Soc Clin Oncol 2001; 20:311b (Abstract #2997).
18. Rizzo JD, Lichtin AE, Woolf SH, et al. Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J Clin Oncol 2002; 19:4083-4107.
19. Rodgers GM, Cella D, Chanan-Khan A, et al. Cancer and treatment-related anemia. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology, vol. 1. Jenkintown, PA: NCCN, 2005.
20. Demetri GD, Kris M, Wade J, et al. Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. J Clin Oncol 1998; 16:3412-3425.
21. Glaspy J, Bukowski R, Steinberg D, et al. Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. J Clin Oncol 1997; 15:1218-1234.
22. Gough IR, Furnival CM, Schilder L, et al. Assessment of the quality of life of patients with advanced cancer. Eur J Cancer Clin Oncol 1983; 19:1161-1165.
23. McCormack HM, Horne DJ, Sheather S. Clinical applications of visual analog scales: a critical review. Psychol Med 1988; 18:1007-1019.
24. FACIT: Functional Assessment of Chronic Illness Therapy. Elmhurst, IL: FACIT, 1997. Available at http://www.facit.org/qview/qlist.aspx. Accessed June 25, 2004.
25. Patrick DL, Gagnon DD, Zagari MJ, et al. Assessing the clinical significance of health-related quality of life (HrQOL) improvements in anaemic cancer patients receiving epoetin alfa. Eur J Cancer 2003; 39:335-345.
26. Straus DJ, Testa M, Riggs SA, et al. Early treatment with epoetin alfa improves anemia, quality of life (QOL), and productivity in patients (pts) with hematologic malignancies and mild anemia during chemotherapy (CT). Blood 2003; 102(suppl):497a (Abstract #1811).
27. Procrit® (epoetin alfa) [prescribing information]. Raritan, NJ: Ortho Biotech Products, LP, January 2005.
28. von Tempelhoff GF, Dietrich M, Hommel G, et al. Blood coagulation during adjuvant epirubicin/cyclophosphamide chemotherapy in patients with primary operable breast cancer. J Clin Oncol 1996; 14:2560-2568.
29. Clahsen PC, van de Velde CJ, Julien JP et al. Thromboembolic complications after perioperative chemotherapy in women with early breast cancer: a European Organization for Research and Treatment of Cancer Breast Cancer Cooperative Group study. J Clin Oncol 1994; 12:1266-1271.
30. Crawford J, Cella D, Cleeland CS, et al. Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy. Cancer 2002; 95:888-895.
31. Shasha D, Cremieux P, Harrison L. Relationship between hemoglobin levels and quality of life during radiation therapy plus concomitant or sequential chemotherapy in patients with cancer and anemia treated with epoetin alfa. J Natl Compr Cancer Network 2004; 2:509-517.
32. Safety of erythropoietin receptor agonists (ERAs) in patients with cancer. Oncologic Drugs Advisory Committee briefing document; March 30, 2004. Raritan, NJ: Johnson & Johnson Pharmaceutical Research & Development, LLC.
33. Bokemeyer C, Oechsle K, Hartmann JT, et al. Treatment-induced anaemia and its potential clinical impact in patients receiving sequential high dose chemotherapy for metastatic testicular cancer. Br J Cancer 2002; 87:1066-1071.
34. Casas F, Viñolas N, Ferrer F, et al. Improvement in performance status after erythropoietin treatment in lung cancer patients undergoing concurrent chemoradiotherapy. Int J Radiat Oncol Biol Phys 2003; 55:116-124.
35. Dunst J, Kuhnt T, Strauss HG, et al. Anemia in cervical cancers: impact on survival, patters of relapse, and association with hypoxia and angiogenesis. Int J Radiat Oncol Biol Phys 2003; 56:778-787.
36. Glaser CM, Millesi W, Kornek GV et al. Impact of hemoglobin level and use of recombinant erythropoietin on efficacy of preoperative chemoradiation therapy for squamous cell carcinoma of the oral cavity and oropharynx. Int J Radiat Oncol Biol Phys 2001; 50:705-715.
37. Munstedt K, Kovacic M, Zygmunt M, et al. Impact of hemoglobin levels before and during chemotherapy on survival of patients with ovarian cancer. Int J Oncol 2003; 23:837-843.
38. Littlewood TJ, Bajetta E, Nortier JWR, et al. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2001; 19:2865-2874.
39. Leyland-Jones B, on behalf of the BEST Investigators Study Group. Breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncol 2003; 4:459-460.
40. Henke M, Laszig R, Rübe C, et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 2003; 362:1255-1260.
41. Möbus VJ, Untch M, du Bois A, et al. Dose-dense sequential chemotherapy with epirubicin (E), paclitaxel (T) and cyclophosphamide (C) (ETC) is superior to conventional dosed chemotherapy in high-risk breast cancer patients (>4 + LN). First results of an AGO-trial. Proc Am Soc Clin Oncol 2004: 22(suppl):6s (Abstract #513).